These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17826303)

  • 1. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.
    Wang J; Li J; Hong X; Tang W; Hu X; Wang B; Guo Y
    Oral Oncol; 2008 May; 44(5):464-70. PubMed ID: 17826303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
    Ngan RK; Yiu HH; Lau WH; Yau S; Cheung FY; Chan TM; Kwok CH; Chiu CY; Au SK; Foo W; Law CK; Tse KC
    Ann Oncol; 2002 Aug; 13(8):1252-8. PubMed ID: 12181249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma.
    Chua DT; Sham JS; Au GK
    Am J Clin Oncol; 2005 Oct; 28(5):464-71. PubMed ID: 16199985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].
    Wang JL; Hong XN; Tang WY; Guo Y; Li J
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):567-9. PubMed ID: 16438860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
    Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
    Hong S; Zhang L
    Chin J Cancer; 2016 Dec; 35(1):100. PubMed ID: 28007026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
    Chen C; Wang FH; Wang ZQ; An X; Luo HY; Zhang L; Chen YC; Xu RH; Li YH
    Oral Oncol; 2012 Nov; 48(11):1146-51. PubMed ID: 22748450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    Hong S; Zhang Y; Yu G; Peng P; Peng J; Jia J; Wu X; Huang Y; Yang Y; Lin Q; Xi X; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C; Fang W; Zhang L
    J Clin Oncol; 2021 Oct; 39(29):3273-3282. PubMed ID: 34379443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
    Ma BB; Tannock IF; Pond GR; Edmonds MR; Siu LL
    Cancer; 2002 Dec; 95(12):2516-23. PubMed ID: 12467065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
    Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
    Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
    You B; Le Tourneau C; Chen EX; Wang L; Jarvi A; Bharadwaj RR; Kamel-Reid S; Perez-Ordonez B; Mann V; Siu LL
    Am J Clin Oncol; 2012 Jun; 35(3):255-60. PubMed ID: 21358293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study.
    Jiang Y; Wei YQ; Luo F; Zou LQ; Liu JY; Peng F; Huang MJ; He QM
    Cancer Invest; 2005; 23(2):123-8. PubMed ID: 15813504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study.
    Kodama H; Kadowaki S; Nakazawa T; Matsubara Y; Narita Y; Honda K; Masuishi T; Taniguchi H; Ando M; Koide Y; Tachibana H; Kodaira T; Sawabe M; Terada H; Beppu S; Nishikawa D; Suzuki H; Hanai N; Muro K
    Anticancer Res; 2024 Mar; 44(3):1227-1232. PubMed ID: 38423663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286).
    Jin T; Li B; Chen XZ
    Oncol Res; 2013; 21(6):317-23. PubMed ID: 25198661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma.
    Yau TK; Lee AW; Wong DH; Yeung RM; Chan EW; Ng WT; Tong M; Soong IS
    Head Neck; 2006 Oct; 28(10):880-7. PubMed ID: 16721741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
    Jamshed A; Hussain R; Iqbal H
    Asian Pac J Cancer Prev; 2014; 15(2):899-904. PubMed ID: 24568516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial.
    Hsieh CY; Lien MY; Lin CY; Lo WJ; Hua CH; Chang WC; Chiu CF; Lin CC
    BMC Cancer; 2022 Feb; 22(1):169. PubMed ID: 35168547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.